Search Results

There are 1448 results for: content related to: Mirabegron in overactive bladder: A review of efficacy, safety, and tolerability

  1. You have full text access to this OnlineOpen article
    Safety and tolerability of the β3-adrenoceptor agonist mirabegron, for the treatment of overactive bladder: results of a prospective pooled analysis of three 12-week randomised Phase III trials and of a 1-year randomised Phase III trial

    International Journal of Clinical Practice

    Volume 68, Issue 8, August 2014, Pages: 972–985, V. W. Nitti, C. R. Chapple, C. Walters, M. B. Blauwet, S. Herschorn, I. Milsom, S. Auerbach and P. Radziszewski

    Version of Record online : 6 APR 2014, DOI: 10.1111/ijcp.12433

  2. You have free access to this content
    Proarrhythmic Safety of Repeat Doses of Mirabegron in Healthy Subjects: A Randomized, Double-Blind, Placebo-, and Active-Controlled Thorough QT Study

    Clinical Pharmacology & Therapeutics

    Volume 92, Issue 6, December 2012, Pages: 696–706, M Malik, E M van Gelderen, J H Lee, D L Kowalski, M Yen, R Goldwater, S K Mujais, M P Schaddelee, P de Koning, A Kaibara, S S Moy and J J Keirns

    Version of Record online : 14 NOV 2012, DOI: 10.1038/clpt.2012.181

  3. You have full text access to this OnlineOpen article
    Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies

    International Journal of Clinical Practice

    Volume 67, Issue 7, July 2013, Pages: 619–632, V. W. Nitti, V. Khullar, P. van Kerrebroeck, S. Herschorn, J. Cambronero, J. C. Angulo, M. B. Blauwet, C. Dorrepaal, E. Siddiqui and N. E. Martin

    Version of Record online : 21 MAY 2013, DOI: 10.1111/ijcp.12194

  4. You have free access to this content
    Mirabegron relaxes urethral smooth muscle by a dual mechanism involving β3-adrenoceptor activation and α1-adrenoceptor blockade

    British Journal of Pharmacology

    Volume 173, Issue 3, February 2016, Pages: 415–428, E C Alexandre, L R Kiguti, F B Calmasini, F H Silva, K P da Silva, R Ferreira, C A Ribeiro, F Z Mónica, A S Pupo and E Antunes

    Version of Record online : 15 JAN 2016, DOI: 10.1111/bph.13367

  5. Persistence with mirabegron therapy for overactive bladder: A real life experience

    Neurourology and Urodynamics

    Volume 36, Issue 2, February 2017, Pages: 404–408, Nisha Pindoria, Sachin Malde, Jennifer Nowers, Claire Taylor, Cornelius Kelleher and Arun Sahai

    Version of Record online : 15 DEC 2015, DOI: 10.1002/nau.22943

  6. You have full text access to this OnlineOpen article
    Patient-reported outcomes with the β3-adrenoceptor agonist mirabegron in a phase III trial in patients with overactive bladder

    Neurourology and Urodynamics

    Volume 35, Issue 8, November 2016, Pages: 987–994, Vik Khullar, Gerard Amarenco, Javier C. Angulo, Mary Beth Blauwet, Jameel Nazir, Isaac A. Odeyemi and Zalmai Hakimi

    Version of Record online : 19 AUG 2015, DOI: 10.1002/nau.22844

  7. An Exploratory Study in Healthy Male Subjects of the Mechanism of Mirabegron-Induced Cardiovascular Effects

    The Journal of Clinical Pharmacology

    Marcel van Gelderen, Matthias Stölzel, John Meijer, Virginie Kerbusch, Christiane Collins and Cees Korstanje

    Version of Record online : 15 JUN 2017, DOI: 10.1002/jcph.952

  8. Patient-reported outcomes from SYNERGY, a randomized, double-blind, multicenter study evaluating combinations of mirabegron and solifenacin compared with monotherapy and placebo in OAB patients

    Neurourology and Urodynamics

    Dudley Robinson, Con Kelleher, David Staskin, Elizabeth R. Mueller, Christian Falconer, Jianye Wang, Arwin Ridder, Matthias Stoelzel, Asha Paireddy, Rob van Maanen, Zalmai Hakimi and Sender Herschorn

    Version of Record online : 13 JUL 2017, DOI: 10.1002/nau.23315

  9. You have free access to this content
    Critical analysis of phase II and III randomised control trials (RCTs) evaluating efficacy and tolerability of a β3-adrenoceptor agonist (Mirabegron) for overactive bladder (OAB)

    BJU International

    Volume 115, Issue 1, January 2015, Pages: 32–40, Marta Rossanese, Giacomo Novara, Ben Challacombe, Alessandro Iannetti, Prokar Dasgupta and Vincenzo Ficarra

    Version of Record online : 27 JUL 2014, DOI: 10.1111/bju.12730

  10. Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a β3-adrenoceptor agonist, in patients with overactive bladder in Asia

    Neurourology and Urodynamics

    Volume 34, Issue 7, September 2015, Pages: 685–692, Hann-Chorng Kuo, Kyu-Sung Lee, Yanqun Na, Rajeev Sood, Shigeru Nakaji, Yosuke Kubota and Kentarou Kuroishi

    Version of Record online : 17 AUG 2014, DOI: 10.1002/nau.22645

  11. You have free access to this content
    Comparative Efficacy and Tolerability of Antimuscarinic Agents and the Selective β3-Adrenoceptor Agonist, Mirabegron, for the Treatment of Overactive Bladder: Which is More Preferable as an Initial Treatment?

    LUTS: Lower Urinary Tract Symptoms

    Minoru KOBAYASHI, Akinori NUKUI and Takao KAMAI

    Version of Record online : 23 DEC 2016, DOI: 10.1111/luts.12153

  12. You have free access to this content
    Efficacy and Safety of the Selective β3-Adrenoceptor Agonist Mirabegron in Japanese Patients with Overactive Bladder: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study

    LUTS: Lower Urinary Tract Symptoms

    Volume 7, Issue 2, May 2015, Pages: 84–92, Osamu YAMAGUCHI, Eiji MARUI, Yasuhiko IGAWA, Masayuki TAKEDA, Osamu NISHIZAWA, Yasushi IKEDA and Sumito OHKAWA

    Version of Record online : 11 MAR 2014, DOI: 10.1111/luts.12053

  13. Mirabegron causes relaxation of human and rat corpus cavernosum: could it be a potential therapy for erectile dysfunction?

    BJU International

    Volume 118, Issue 3, September 2016, Pages: 464–474, Serap Gur, Taylor Peak, Faysal A. Yafi, Philip J. Kadowitz, Suresh C. Sikka and Wayne J.G. Hellstrom

    Version of Record online : 26 MAY 2016, DOI: 10.1111/bju.13515

  14. A prospective study of elderly initiating mirabegron versus antimuscarinics: Patient reported outcomes from the Overactive Bladder Satisfaction Scales and other instruments

    Neurourology and Urodynamics

    Suvapun Bunniran, Cralen Davis, Rita Kristy, Daniel Ng, Carol R. Schermer, Claudia Uribe and Brandon T. Suehs

    Version of Record online : 31 MAR 2017, DOI: 10.1002/nau.23271

  15. You have free access to this content
    Mirabegron 50 mg once-daily for the treatment of symptoms of overactive bladder: An overview of efficacy and tolerability over 12 weeks and 1 year

    International Journal of Urology

    Volume 21, Issue 10, October 2014, Pages: 960–967, Christopher R Chapple, Steven A Kaplan, David Mitcheson, Mary Beth Blauwet, Moses Huang, Emad Siddiqui and Vik Khullar

    Version of Record online : 4 AUG 2014, DOI: 10.1111/iju.12568

  16. Long-term treatment with the beta-3 adrenoceptor agonist, mirabegron ameliorates detrusor overactivity and restores cyclic adenosine monophosphate (cAMP) levels in obese mice

    Neurourology and Urodynamics

    Volume 36, Issue 6, August 2017, Pages: 1511–1518, Fabiano B. Calmasini, Mariana G. de Oliveira, Eduardo C. Alexandre, Fábio H. da Silva, Carmem P.V. da Silva, Tuany Z. Candido, Edson Antunes and Fabíola Z. Mónica

    Version of Record online : 29 OCT 2016, DOI: 10.1002/nau.23171

  17. Clinical efficacy and safety of mirabegron and imidafenacin in women with overactive bladder: A randomized crossover study (the MICRO study)

    Neurourology and Urodynamics

    Volume 36, Issue 4, April 2017, Pages: 1097–1103, Kazumasa Torimoto, Chie Matsushita, Atsushi Yamada, Daisuke Goto, Yoshihiro Matsumoto, Yukinari Hosokawa, Makito Miyake, Katsuya Aoki, Akihide Hirayama, Nobumichi Tanaka and Kiyohide Fujimoto

    Version of Record online : 6 JUN 2016, DOI: 10.1002/nau.23050

  18. The β3-adrenoceptor agonist mirabegron increases human atrial force through β1-adrenoceptors: an indirect mechanism?

    British Journal of Pharmacology

    Volume 174, Issue 16, August 2017, Pages: 2706–2715, Weilan Mo, Martin C Michel, Xiang Wen Lee, Alberto J Kaumann and Peter Molenaar

    Version of Record online : 7 JUL 2017, DOI: 10.1111/bph.13897

  19. Evaluation of the Pharmacokinetic Interaction Between the β3-Adrenoceptor Agonist Mirabegron and the Muscarinic Receptor Antagonist Solifenacin In Healthy Subjects

    Clinical Pharmacology in Drug Development

    Volume 2, Issue 3, July 2013, Pages: 255–263, Walter J. J. Krauwinkel, Virginie M. M. Kerbusch, John Meijer, Reiner Tretter, Gregory Strabach and E. Marcel Van Gelderen

    Version of Record online : 14 MAY 2013, DOI: 10.1002/cpdd.37

  20. You have free access to this content
    A proof-of-concept study: Mirabegron, a new therapy for overactive bladder

    Neurourology and Urodynamics

    Volume 32, Issue 8, November 2013, Pages: 1116–1122, Christopher R. Chapple, Gerard Amarenco, Miguel A. López Aramburu, Karel Everaert, Josef Liehne, Malcolm Lucas, Viktor Vik, Arwin Ridder, Robert Snijder, Osamu Yamaguchi and on behalf of the BLOSSOM Investigator Group

    Version of Record online : 19 FEB 2013, DOI: 10.1002/nau.22373